| Produktname |
GW501516 |
| FALL |
317318-70-0 |
| Produktkategorien |
SARMs(Selective androgen receptor modulator) |
| Lagertemperatur. |
Kühlschrank |
| Aussehen |
White Powders |
| Reinheit |
99% |
| Verwendung |
It is a potent and tissue-selective androgen receptor modulator (Charme). |
Product description
GW501516 (GW1516 or GSK-516) is a drug that acts as a PPAR delta regulator. GW 501516 activates AMP-activated protein kinases and stimulates glucose uptake in skeletal muscle tissue, GW 501516 has been shown to reverse the metabolic abnormalities of obese men with pre-diabetic metabolic syndrome, most likely by stimulating fatty acid oxidation. Potential treatments for obesity and related disorders have been proposed, particularly when used in conjunction with the synergistic compound AICAR, since the combination has been shown to significantly enhance exercise tolerance in animal studies.
GW501516 (also known as GW-501,516, GW1516, GSK-516 and Endurobol) are PPARδ receptors. It activates the same pathway through exercise activation, including PPARδ and AMP-activated protein kinases. Has been investigated for potential treatments for obesity, diabetes, dyslipidemia and cardiovascular disease. When combined with AICAR, GW501516 has a synergistic effect: it has been shown that the combination significantly increases exercise tolerance in animal studies compared to the use of compounds alone.
Product Features
GW501516 is a selective agonist (activator) of the PPAR delta receptor. PPARδ with PPARα and PPARγ with & gt; 1000-fold selectivity showed high affinity (Ki = 1 nM) and titer (EC50 = 1 nM).
In rats, the combination of GW501516 and PPAR delta recruited the auxiliary activator PGC-1a. PPARδ / coactivator complex regulates the expression of proteins involved in energy consumption. In Ergänzung, in rats treated with GW501516, the increase in fatty acid metabolism and diet-induced obesity and type II diabetes were observed in skeletal muscle. In obese rhesus monkeys, GW501516 increased high density lipoprotein (HDL) and reduced very low density lipoprotein (VLDL). PPAR delta agonists increase the HDL mechanism as appears to be the result of increased expression of cholesterol transporter ABCA1.
Verkaufsleiter